MD Anderson and collaborators to launch project studying T cells on International Space Station
The University of Texas MD Anderson Cancer Center and collaborators are initiating a research project that will send T cells to the International Space Station (ISS) to study the effects of prolonged microgravity on cell differentiation, activation, memory and exhaustion. These results will be further analyzed on Earth to uncover signaling pathways and identify potential immune targets that can improve treatment strategies for patients...
MD Anderson and UroGen Pharma announce strategic research collaboration to advance investigational treatment for high-grade bladder cancer
The University of Texas MD Anderson Cancer Center and UroGen Pharma Ltd. today announced a strategic three-year collaboration agreement to...
Immunology study finds protein critical to T cell metabolism and anti-tumor immune response
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a protein called NF-kappa B-inducing kinase (NIK) is...
Combination biomarker predicts response to immune checkpoint therapy in patients with advanced bladder cancer
In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors, according to researchers from The University of Texas MD Anderson Cancer Center.
The study, published today in Science Translational Medicine, used multi-platform analyses of tumor samples...
MD Anderson and Takeda Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform
The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited today announced an exclusive license agreement...
Immunotherapy combination generates responses against castration-resistant metastatic prostate cancer
Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy...
VISTA checkpoint implicated in pancreatic cancer immunotherapy resistance
Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment...
MD Anderson immunologist Jim Allison awarded Nobel Prize
Jim Allison, Ph.D., chair of Immunology and executive director of the immunotherapy platform at The University of Texas MD Anderson Cancer...
MD Anderson immunotherapy expert Sharma wins Coley Award
Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology at The University of Texas MD Anderson...
MD Anderson hosts annual evening fun run benefiting melanoma research
The University of Texas MD Anderson Cancer Center and The AIM at Melanoma Foundation are proud to co-host the ninth annual AIM for the CURE...